Merck releases update on cardiovascular development programs
Merck is planning to file applications for vorapaxar, an investigational anti-thrombotic medicine in the US and the European Union in 2013 following the review of the clinical trial
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
Phase III randomised, open-label EMILIA study has met co-primary efficacy endpoints of overall survival and progression-free survival (PFS). The study showed that trastuzumab emtansine (T-DM1) significantly extended the
The contracts include a two-year application management outsourcing engagement for a university-affiliated children’s hospital and business process re-engineering and application implementation services for a regional health insurer for